Standard Bariatrics
Year founded: 2014
Top executive: Matt Sokany, CEO
Website: standardbariatrics.com
Describe your company. Standard Bariatrics is a clinically staged, medical device company funded by private investors, including RiverVest Venture Partners, Hatteras Venture Partners along with local investment support from Queen City Angels, CincyTech and Accelerant in Dayton. We develop surgical tools for sleeve gastrectomy, the most common weight loss surgical procedure.
What makes your product innovative? Our first FDA cleared device, Standard Clamp, has now been used in over 8,000 sleeve gastrectomy procedures, with clinical evidence demonstrating reduced post-operative gastro-esophageal reflux disease and shortened length of stay.
What’s your biggest success to date? The FDA clearance of Titan SGS for an IDE human clinical trial which started this summer.
What's the next big goal on the horizon? With the successful completion of the IDE study and resubmission of our 510K later this year, we anticipate FDA clearance and launch of the Titan SGS into the U.S. in 2021. The global stapling market for gastric stapling is approaching $1 billion dollars globally.
